BridgeBio Builds on Positive Phase III Data for Acoramidis in ATTR-CM

BridgeBio Pharma on Wednesday unveiled additional findings from the Phase III ATTRibute-CM study of acoramidis, showing that the oral drug candidate’s effects on serum transthyretin levels correlate with improved clinical outcomes in patients with transthyretin amyloid cardiomyopathy.